Health X Platform Ltd · NSE:HEALTHX
Health X Platform — Sastasundar Ventures — Investor Presentation (June 2022)
22 slides from Health X Platform's investor presentation, June 2022
Slide 1: Intimation to BSE and NSE under Regulation 30
Date: 02-06-2022 To The General Manager Department of Corporate Services BSE Limited (Designated Stock Exchange) Phiroze Jeejeebhoy Tower Dalal Street, Mumbai - 400 001 SASTASUNDAR VENTURES LIMITED Azimganj House, 2nd Floor, 7 Abanindra Nath Thakur Sarani (Formerly Camac Street), Kolkata 700017, Ind
Slide 2: Investor Presentation June 2022
Investor Presentation June 2022 SastaSundar Ventures Limited
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Sastasundar Ventures Limited (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: Quarterly Highlights
Quarterly Highlights 3
Slide 5: Q4 & FY22 Financial Highlights
Q4 & FY22 Financial Highlights Rs. In Crs Revenue from Operations Gross Profit 7.9% 6.1% 8.8% 6.5% +15.4% -14.7% 623.0 47.5 540.0 40.5 +19.2% -8.6% 132.2 157.6 10.5 9.6 Q4FY21 Q4FY22 FY21 FY22 Q4FY21 Q4FY22 FY21 FY22 Gross Profit Revenue ✓ Gross Profit for Q4FY22 & FY22 stood at Rs. 9.6 crs & Rs. 40
Slide 6: Q4 & FY22 Consolidated Profit & Loss Statement
Q4 & FY22 Consolidated Profit & Loss Statement Particulars (Rs. Crs) Q4 FY22 Q4 FY21 Y-o-Y Q3 FY22 Q-o-Q FY22 FY21 Y-o-Y Revenue from Operations 157.6 132.2 19.2% 141.1 11.7% 623.0 540.0 15.4% Cost of Materials Consumed 148.0 121.7 132.9 582.5 492.5 Gross Profit 9.6 10.5 8.2 40.5 47.5 GP % 6.1% 7.9%
Slide 7: Management Comments
Management Comments Commenting on the results and performance for Q4 & FY22, Mr. B.L. Mittal, Founder & Executive Chairman said: “When the world continued to face unprecedented challenges in the business environment, this year has been a landmark year in the history of the company, in which we succe
Slide 8: Deal & Future Strategy
Deal & Future Strategy 7
Slide 9: Flipkart - SastaSundar Deal Structure
Flipkart - SastaSundar Deal Structure SastaSundar Ventures Ltd.(SVL) Mitsubishi Corporation & Rohto Pharmaceuticals 28% Shareholding 72% Shareholding SastaSundar Healthbuddy Limited (SHBL) Wholesale business to support Flipkart Health Pvt. Ltd Seller Pharmacy Network of SastaSundar.Com 100% 100% 24.
Slide 10: Financial Details of the Deal
Financial Details of the Deal • SML has received the amount of INR 372.00 crores from Flipkart Health Private Limited on account of allotment of equity shares of SML to Flipkart Health Private Limited; (holding 75.1% of Equity share capital of SML) • SHBL has also received INR 689.76 Crores from Fli
Slide 11: Future Macro Strategy
Future Macro Strategy Macro Strategy Focus & Growth ‘Digital Platform of Healthcare’ Pharmacy Wellness Diagnostic Develop Leverage Deliver 3T 2C 3C Team Cash Flow Customer Base Technology Customer Experience Capital Trust Community Wellbeing 10 Health & Happiness
Slide 12: Future Micro Strategy
Future Micro Strategy Micro Strategy B2C Platform B2B Platform Genu Path Labs • Expand & Grow network of Seller • Expand – PAN India, Accelerate • Expand Diagnostic Network in Eastern Pharmacies – PAN India growth India • Expand fulfilment capabilities – • Leverage scale to Maximise • Leverage consu
Slide 13: Historical Financial Highlights
Historical Financial Highlights 12
Slide 14: FY22 Financial Highlights
FY22 Financial Highlights Rs. In Crs Q4 Revenue Revenue from from Operations Operations Gross Profit Q3 Q2 4.5% 8.8% 6.5% Q1 62% 137% 622 48 540 158 +20% 11 41 132 385 10 141 +5% 12 116 134 8 155 +11% 17 13 103 140 10 5 92 4 134 169 +26% 5 12 13 74 3 FY20 FY21 FY22 FY20 FY21 FY22 Gross Profit Revenu
Slide 15: Historical Consolidated Profit & Loss Statement
Historical Consolidated Profit & Loss Statement Particulars (Rs. Crs) Mar-22 Mar-21 Mar-20 Mar-19 Mar-18 Revenue from Operations 623.0 540.0 384.0 215.6 148.3 Cost of Materials Consumed 582.5 492.5 366.9 199.5 140.4 Gross Profit 40.5 47.5 17.1 16.1 7.9 GP % 6.5% 8.8% 4.5% 7.5% 5.3% Employee Benefits
Slide 16: Historical Consolidated Balance Sheet
Historical Consolidated Balance Sheet Equity & Liabilities (Rs. Crs) Mar-22 Mar-21 Mar-20 Mar-19 Mar-18 Assets (Rs. Crs) Mar-22 Mar-21 Mar-20 Mar-19 Mar-18 Equity Share Capital 31.8 31.8 31.8 31.8 31.8 Property, Plant and Equipment 57.2 57.3 60.2 62.7 64.8 Other Equity 1175.7 197.6 214.4 168.6 171.3
Slide 17: Historical Consolidated Cash Flow Statement
Historical Consolidated Cash Flow Statement Particulars (Rs. Crs) Mar-22 Mar-21 Mar-20 Mar-19 Mar-18 Cash Flow from Operating Activities Profit before Tax 1,109.5 (16.4) (57.6) (41.8) (12.4) Adjustment for Non-Operating Items 1,151.0 (3.2) 4.8 7.8 5.4 Operating Profit before Working Capital Changes
Slide 18: About Us
About Us 17
Slide 19: Backed by Globally Acclaimed Investors; Auditors
Backed by Globally Acclaimed Investors Mitsubishi Corporation Rohto Pharmaceutical Co., Ltd. At Business Level At Consolidated Level Auditors S.R. Batliboi & Co. LLP JKVS & Co. (a member firm of EY) 18 Health & Happiness
Slide 20: Experienced Board of Directors
Experienced Board of Directors ▪ FCA, FCS and FCM by education and has an experience of ▪ FCA by education and is a seasoned entrepreneur with more than 20 years working as an entrepreneur and a more than 20 years of demonstrated experience in social worker. scaling businesses from scratch. ▪ Areas
Slide 21: Join us for Prayers
Join us for Prayers 20 Health & Happiness
Slide 22: Thank You
Contact Information Thank You For Further Information, please contact: Company: Investor Relations Partner: Sastasundar Ventures Limited Orient Capital (a division of Link Group) CIN: L65993WB1989PLC047002 Payal Dave Rasika Sawant Mr. Pratap Singh – Company Secretary payal.dave@linkintime.co.in Rasi
Sastasundar Ventures — Investor Presentation (June 2022) on 6ix